Impax price target raised to $35 from $27 at Piper Jaffray Piper Jaffray raised its price target for Impax shares to $35 saying it sees more upside potential than downside risk even with the absence of a resolution of the FDA warning letter related to the Hayward manufacturing facility. Piper reiterates an Overweight rating on the stock.
Impax downgraded to Sell from Neutral at UBS UBS downgraded Impax Laboratories to Sell saying the risk/reward is biased to the downside following the recent rally in shares. UBS attributes the recent run-up in shares to expectations the company will do more deals or get acquired. The firm does not see either scenario driving the stock much above current levels "any time soon." It keeps a $36 price target for Impax shares.